切换至 "中华医学电子期刊资源库"
高级检索
中华结直肠疾病电子杂志

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (05) : 424 -427. doi: 10.3877/cma.j.issn.2095-3224.2016.05.011

所属专题： 专题评论； 文献；

论著

腹腔内注射贝伐珠单抗治疗结直肠癌患者恶性腹腔积液的疗效和安全性评价
钟漓1,†(), 赵志1, 朱小宝1, 冉福林1, 陈霄1   
  1. 1. 541000　桂林医学院附属医院胃肠外科
  • 收稿日期:2016-05-17 出版日期:2016-10-25
  • 通信作者: 钟漓
  • 基金资助:
    吴阶平医学基金资助项目(No.320.6750.13390)

The short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab

Li Zhong1,†(), Zhi Zhao1, Xiaobao Zhu1, Fulin Ran1, Xiao Chen1   

  1. 1. Department of Gastrointestinal Surgery, Guilin Medical College Affiliated Hospital, Guilin 541000, China
  • Received:2016-05-17 Published:2016-10-25
  • Corresponding author: Li Zhong
  • About author:
    Corresponding author: Zhong Li, E-mail:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

钟漓, 赵志, 朱小宝, 冉福林, 陈霄. 腹腔内注射贝伐珠单抗治疗结直肠癌患者恶性腹腔积液的疗效和安全性评价[J/OL]. 中华结直肠疾病电子杂志, 2016, 05(05): 424-427.

Li Zhong, Zhi Zhao, Xiaobao Zhu, Fulin Ran, Xiao Chen. The short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(05): 424-427.

目的

探讨腹腔内注射贝伐珠单抗治疗恶性腹腔积液的近期疗效及安全性；

方法

收集46例桂林医学院附属医院胃肠外科2010年3月至2014年5月伴有难以控制的恶性腹腔积液的晚期结直肠癌患者。检测其腹腔积液中VEGF含量；并利用单因素生存分析对比两组患者的预后。

结果

对照组的血清VEGF平均值为（671.8±499.15）pg/mL，与治疗组［平均值为（665.19.19±499.15）pg/mL］相比差异无统计学意义。治疗组中，治疗前腹腔积液VEGF量的平均值为（1 225.11±609.71）pg/mL，无穿刺中位生存时间为6个月（1~21个月）。与对照组相比，治疗组的穿刺引流时间明显延长（t值=6.328，P<0.05）。治疗后，腹腔积液的VEGF量（317.69±172.14）pg/mL，与治疗前相比差异存在统计学意义。治疗后的血清VEGF平均值为（170.61±115.92）pg/mL，与治疗前差异具有统计学意义。在生存分析中，治疗组的预后明显好于对照组（P<0.05）。

结论

对于一部分合适的患者，腹腔内注射贝伐珠单抗对于恶性腹腔积液的治疗可能是一种有效地、安全的治疗手段。

关键词: 结直肠肿瘤, 治疗, 抗VEGF, 贝伐珠单抗, 恶性腹水
Objective

To investigate the short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab.

Methods

46 colorectal cancer patients with uncontrolled malignant ascites at the A?liated Hospital of Guilin Medical College from 2010 to 2014 were enrolled in this study. Investigate the VEGF value of malignant ascites and analyze the survival time of two groups.

Results

The mean VEGF value of control group is 671.8±499.15 pg/mL, and has not statistically significant than treatment group (mean value: 1225.11±609.71 pg/mL). In treat group, the mean VEGF value is 1225.11±609.71 pg/mL before treatment. The median survival time of non-paracentesis is 6 months (1~21 months). In contrast with control group, the time of non-paracentesis is significantly longer in treatment group (6.328, P<0.05). After treatment, the mean VEGF value is 317.69±172.14 pg/mL in treatment group. There is statistically significant than control group. In survival analysis, treatment group shows signi?cantly better overall survival (OS) (P<0.05).

Conclusion

For a part of appropriate patients, treated with intraperitoneal injection of bevacizumab is an effective and safety method.

Key words: Colorectal neoplasm, Therapy, Anti-VEGF, Bevacizumab, Malignant ascites
表1 对照组与治疗组中血清VEGF与无穿刺生存时间对比（±s）
组别 例数 血清VEGF（pg/mL） 无穿刺生存时间（月）
对照组 20 671. 8±499. 15 2. 75±1. 44
治疗组 26 665. 19±499. 15 6. 92±3. 47
t值 ? 10. 246 6. 328
P值 ? 0. 965 <0. 001
表2 治疗组治疗前后VEGF值的比较（±s）
组别 例数 血清VEGF（pg/mL） 腹水VEGF（pg/mL）
治疗前 26 665. 19±499. 15 1225. 11±609. 71
治疗后 26 170. 61±115. 92 317. 69±172. 14
t值 ? 5. 841 4. 332
P值 ? <0. 001 <0. 001
图1 治疗组与对照组的总体生存的比较
[1]
Torre LA,Bray F,Siegel RL, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians, 2015, 65(2): 87-108.
[2]
Sinclair P,Singh A,Riaz AA, et al. An unsolved conundrum: the ideal follow-up strategy after curative surgery for colorectal cancer. Gastrointestinal endoscopy, 2012, 75(5): 1072-1079.
[3]
Becker G,Galandi D,Blum HE. Malignant ascites: systematic review and guideline for treatment. European journal of cancer, 2006, 42(5): 589-597.
[4]
Montero E,Miguel J,Lopez-Alvarez J. Care of patients with ascites. The New England journal of medicine, 1994, 330(25): 1828.
[5]
Liu Y,Luan L,Wang X. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. OncoTargets and therapy, 2015, 8: 1061-1068.
[6]
Hurwitz HI,Fehrenbacher L,Hainsworth JD, et al. Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. Journal of Clinical Oncology, 2005, 23(15): 3502-3508.
[7]
Adam RA,Adam YG. Malignant ascites: past, present, and future. Journal of the American College of Surgeons, 2004, 198(6): 999-1011.
[8]
Saada E,Follana P,Peyrade F, et al. Pathogenesis and management of refractory malignant ascites. Bulletin du cancer, 2011, 98(6): 679-687.
[9]
Yabushita H,Shimazu M,Noguchi M, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncology Reports, 2003, 10(1): 89-95.
[10]
Atanackovic D,Cao Y,Kim J-W, et al. The local cytokine and chemokine milieu within malignant effusions. Tumor Biology, 2008, 29(2): 93-104.
[11]
Cavazzoni E,Bugiantella W,Graziosi L, et al. Malignant ascites: pathophysiology and treatment. International journal of clinical oncology, 2013, 18(1): 1-9.
[12]
Smolle E,Taucher V,Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer research, 2014, 34(4): 1553-1561.
[13]
Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul, 1995, 35: 293-301.
[14]
Folkman J. Tumor angiogenesis: therapeutic implications. The New England journal of medicine, 1971, 285(21): 1182-1186.
[15]
Numnum TM,Rocconi RP,Whitworth J, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecologic Oncology, 2006, 102(3): 425-428.
[16]
el-Shami K,Griffiths E,Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. The oncologist, 2007, 12(5): 518-523.
[17]
Pichelmayer O,Zielinski C,Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. New England Journal of Medicine, 2005, 353(7): 740-741.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(08): 778-784.
[2] 易柏成, 李旭光, 王容容, 王新璇. 数字化3D打印导板应用于上前牙钙化根管治疗2例[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 385-390.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[7] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[8] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[9] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[10] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[11] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？